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ABSTRACT 
Type 2 diabetes (T2D) spreads like an epidemic in today’s society, and there 
is a great need for new and improved treatments. T2D is characterized by 
hyperglycemia, resulting from impaired insulin production and insulin 
resistance in peripheral tissues. Incretin hormones, such as glucagon-like 
peptide-1 (GLP-1), secreted from L-cells dispersed along the intestinal tract, 
potentiate meal-stimulated insulin secretion in a glucose-dependent manner. 
Defective GLP-1 secretion has been indicated in T2D and administration of 
GLP-1 to T2D patients restores glucose-induced insulin secretion and 
normalizes glycemia, making stable analogs of GLP-1 among the best 
available treatments for T2D today. However, enhancing endogenous GLP-1 
production/secretion by direct stimulation of GLP-1 secretion/promotion of 
growth and viability of L-cells may be a novel and more physiological option 
in incretin-based diabetes therapy. The aim of this work was to determine the 
effect of diabetic conditions and anti-diabetic agents on GLP-1-producing 
cells, in order to unravel some of the mechanisms regulating growth, survival 
and function of this cell type. 
Studies I-III were performed in vitro using the murine GLUTag cell line as a 
model. In study I, direct effects of metformin on apoptosis, and function of 
GLP-1-secreting cells were determined. Simulated diabetic hyperlipidemia 
resulted in increased caspase-3 activity and DNA fragmentation, indicating 
lipoapoptosis. Metformin treatment significantly decreased this lipoapoptosis 
in conjunction with increased phosphorylation of AMPK. In addition, 
metformin treatment stimulated GLP-1 secretion. 
In study II, we determined molecular mechanisms mediating lipotoxicity and 
metformin-induced lipoprotection in GLP-1-secreting cells. Diabetic 
hyperlipidemia was simulated in this cell system by addition of the fatty acid 
palmitate. Palmitate increased ROS production in GLP-1-secreting cells, and 
the lipotoxic effects of palmitate were abolished in the presence of the 
antioxidant Trolox. Further, palmitate phosphorylated p38 MAPK and 
inhibition of this enzyme significantly reduced lipoapoptosis. Pre-incubation 
with metformin further increased palmitate-induced ROS production, while 
significantly reducing the expression of p38 MAPK. 
Study III focused on direct effects of insulin and exendin-4/GLP-1 on 
lipoapoptosis and function of GLP-1-secreting cells. The GLP-1R was found 
to be expressed in the GLUTag cells, and diabetic lipotoxicity was partially 
inhibited by pre-incubation with insulin or the stable GLP-1 analog exendin-
4. The lipoprotective effect of exendin-4 was GLP-1R-dependent, while 
independent of PKA activity. In addition, both insulin and exendin-4 
significantly stimulated acute and long term GLP-1 secretion in the presence 
of glucose. In study IV, we investigated if a high fat diet (HFD) reduces the 
number of enteroendocrine GLP-1-secreting L-cells in C57/Bl6 mice. We 
also determined the effects of a HFD on GLP-1 plasma levels and possible 
effects on these parameters by metformin treatment. A HFD rapidly induced a 
diabetic phenotype with increased HbA1c levels, as well as fasting plasma 
insulin levels in conjunction with reduced oral glucose tolerance – indicating 
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the manifestation of insulin resistance. A 14 day oral administration of 
metformin reduced HbA1c, fasting insulin and prandial FFA levels. The 
number of L-cells was significantly reduced after 12 weeks on a HFD, while -
- in contrast -- there was a clear trend toward increased prandial plasma GLP-
1 levels despite reduced food intake in HFD-fed mice. 
These findings may be of pathogenic significance not only in understanding 
mechanisms of the impaired incretin response characterizing T2D patients, 
but may also be harnessed to therapeutic advantage in efforts to enhance 
endogenous GLP-1 production. Such an approach has hitherto received little 
attention but may be superior to contemporary incretin-based antidiabetic 
therapy, which does not faithfully mimick physiologic GLP-1 release in for 
instance terms of secretory pattern (e.g. pulsatility) and actions on 
topographically adjacent hormone receptors (e.g. in the portal vein). 
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INTRODUCTION 
 
1.1 TYPE 2 DIABETES 
T2D is a syndrome characterized by disordered metabolism, resulting in 
inappropriately high blood sugar (hyperglycemia). According to the World 
Health Organization (WHO), diabetes is diagnosed by fasting plasma glucose 
levels > 7 mmol/l, or by a plasma glucose concentration > 11.1 mmol/l 2 h 
following an oral glucose load. The characteristic feature of the disease results 
from a combination of impaired insulin production from the pancreatic β-cells 
and insulin resistance in peripheral tissues. The most common long-term 
complication is cardiovascular disease which stands for 75-80 % of all deaths 
related to diabetes [1]. Clinical management of the disease involves a 
combination of dietary treatment, application of oral anti-diabetic drugs and 
oftentimes also insulin injections. Diabetes is widespread and it is the fourth 
leading cause of death in the U.S. [1]. According to the WHO, its incidence is 
increasing rapidly and is estimated to double by the year 2030 and the 
expenses to diabetes have been shown to be a major drain on health- and 
productivity-related resources for healthcare systems and governments. In the 
U.S. alone, the annual cost for diabetes amounts to the humongous sum of $ 
174 billion, of which ~ 97 % is targeted to T2D. Improved glycemia is still the 
main focus of T2D therapy and glycated hemoglobin (HbA1c) levels of 5-6 % 
(DCCT standard; corresponding to 31-42 mmol/mol by IFCC standard) are 
recommended treatment goals. However, more than 50 % of patients with 
T2D have a HbA1c level of >7 % (53 mmol/mol by IFCC standard) and are 
thus inadequately controlled [2].  
 
1.2 THE INCRETIN SYSTEM AND GLP-1  
1.2.1 GLP-1 and the GLP-1 receptor 
Glucagon-like peptide-1 (GLP-1) is a small peptide hormone, released from 
enteroendocrine intestinal L-cells in response to hormonal, neural and nutrient 
stimuli, which exerts numerous pleiotropic effects in various tissues [3]. The 
most well-known action of GLP-1 is enhanced insulin release in the context 
of hyperglycemia [4]. The biologically active forms of GLP-1 are GLP-1(7-
37) and GLP-1(7-36)NH2, the actions of which are exerted through a G 
protein-coupled receptor. The GLP-1 receptor (GLP-1R) was first cloned 
from rat pancreatic islets [5] and is widely distributed and expressed in 
several organs: pancreatic islets, stomach, heart, intestine, adipocytes, lung 
and kidney, as well as in the CNS [6-10]. Although previously not believed to 
be expressed in hepatocytes, some recent studies have reported the presence 
of the GLP-1R on human hepatocytes [11], and GLP-1 has been shown to 
promote glycogen accumulation in rat hepatocytes [12-13], independent of 
changes in insulin [14]. 
Activation of the GLP-1R results in stimulation of adenylate cyclase, 
increased intracellular cAMP levels [15], and subsequent activation of protein 
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kinase A (PKA) [16] and exchange protein activated by cAMP 2 (EPAC2) 
[17].  
 
 
1.2.2 The incretin effect and pancreatic actions of GLP-1 
Blood glucose is maintained within normal ranges by sophisticated 
mechanisms under physiological conditions. In diabetes, insufficient insulin 
production, glucagon excess and peripheral insulin resistance result in 
hyperglycemia and other metabolic disturbances. Under physiological 
conditions, glucose is the major stimulator of insulin secretion. Incretin 
hormones such as glucose-dependent insulinotropic polypeptide (GIP) and 
GLP-1 serve to augment meal-stimulated insulin secretion from β-cells in a 
glucose-dependent manner [18]. The incretin effect is described as the ability 
of gastrointestinal hormones such as GLP-1, released in response to food 
intake, to stimulate insulin release from the endocrine pancreas [19]. The 
incretin effect can be quantified by measuring insulin secretion after oral 
glucose ingestion and after intravenous infusion of glucose resulting in an 
equivalent rise in plasma glucose concentration, and accounts for 20 to 60 % of 
the overall postprandial insulin secretion in healthy subjects [20].  
Intracellular cAMP levels are critical for normal glucose-stimulated insulin 
secretion (GSIS) [21]. Consequently, receptors, such as the GLP-1R, that are 
associated with increased cAMP levels have the potential to play an important 
part in GSIS. GLP-1-mediated activation of PKA/EPAC results in closure of 
ATP-sensitive K+ channels, depolarization of the plasma membrane and 
opening of voltage-gated Ca2+ channels, influx of Ca2+ and the subsequent 
triggering of insulin exocytosis [22-25]. Activation of the GLP-1R also 
increases intracellular Ca2+ through Ca2+ release from the endoplasmic 
reticulum via inositol 1,4,5 trisphosphate receptors activated by PKA and 
ryanodine receptors activated by EPAC2 [26-27]. However, contribution of 
other signaling pathways, including protein kinase C (PKC) through 
activation of phospholipase C (PLC) and phosphatidylinositol 3-kinase 
gamma (PI3-Kγ), in GSIS has also been reported [20, 28-29]. Previous 
studies have shown that activation of PI3-kγ plays an essential role in the 
regulation of GLP-1-stimulated insulin secretion, and that PI3-Kγ deficiency 
may result in dissociation between cAMP levels and GSIS [28].  
In vitro and in vivo studies show that GLP-1, and its analogs, induce β-cell 
proliferation in normal rodent islets and insulinoma cell lines [30-32], and 
that GLP-1R activation also reduces β-cell apoptosis in purified rodent and 
human islets as well as β-cell lines after exposure to many cytotoxic agents, 
including reactive oxygen species (ROS), palmitate, and dexamethasone 
[33]. To stimulate β-cell proliferation and survival, GLP-1 acts through PI-
3K/protein kinase B (PKB) [34]. Specifically, promotion of forkhead box 
protein O1 (FoxO1) nuclear exclusion and subsequent up-regulation of the 
transcription factors pancreatic duodenal homeobox 1 (PDX-1) and forkhead 
box protein A2 (Foxa2) expression via PI3K-dependent activation of PKB 
and cAMP/PKA-dependent activation of cAMP response element-binding 
protein (CREB), lead to up-regulation of insulin receptor substrate 2 (IRS2) 
protein expression and activation of PKB [35]. In addition, a role for EPAC 
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in GLP-1R-mediated reductions of induced ROS production has also been 
demonstrated [36]. 
GLP-1 also decreases glucagon secretion from the pancreas in the presence of 
hyperglycemia, an effect that ceases at glucose levels < 4 mmol/l, thus also 
involving low risk of hypoglycemic side effects [4]. However, whether this 
inhibition of glucagon secretion is a direct effect on the glucagon-secreting α-
cells or an indirect effect through insulin is still debated. However, there are 
reports on low expression of the GLP-1R on α-cells. Further, it has been shown 
that in α-cells elevation of intracellular cAMP levels exerts both inhibitory and 
stimulatory effects via activation of PKA and EPAC, respectively [37]. 
Specifically, the very low GLP-1R expression results in small increases in 
cAMP as compared to activation of G protein-coupled adrenalin receptors, 
which are abundant on the α-cells. Consequently, GLP-1R activation induces 
inhibitory PKA activity, but does not induce the stimulatory EPAC activity 
seen in response to adrenalin [37]. 
 
1.2.3 Extrapancreatic actions of GLP-1 
A portal signal is of importance for the glucose lowering effects of GLP-1 
[38] and intraportal GLP-1 increases insulin secretion and glucose clearance 
[39]. Further, a role for GLP-1 in the portal glucose sensor has been reported 
[40]. As the GLP-1 produced in the L-cells is drained into the portal circulation 
prior to hepatic passage and extraction, this particular route may not be targeted 
by the therapeutic injection of GLP-1 analogs used in contemporary T2D 
therapy. Conversely, enhancing short- or long-term endogenous GLP-1 
production may thus offer treatment benefits as compared to exogenous GLP-1 
replacement therapy.   
GLP-1 regulates gastrointestinal motility and gastric secretion by mechanisms 
dependent on vagal innervations [41-44]. In addition, pharmacological levels 
of GLP-1 inhibit both gastric emptying and gastric acid secretion in human 
subjects [45]. This inhibitory effect of GLP-1 on gastric emptying may 
account for the glucose-lowering effects observed not only in T2D but also in 
type 1 diabetic patients [46]. 
The GLP-1R is expressed throughout the CNS, where GLP-1 exerts actions 
regulating satiety and food intake [20, 47]. Further, GLP-1R activation in the 
CNS has been shown to exert neuroprotection, with beneficial effects in 
neurological disorders, including Alzheimer’s and Parkinson’s disease [48-
50].  
GLP-1 has also been shown to exert effects on fat and muscle cells in vitro, 
including increased fatty acid synthesis [51] and increased glucose uptake 
[52] in adipocytes, as well as stimulated glycogen synthesis and glucose 
utilization in cultured myotubes [53]. However, the nature and physiological 
relevance of these actions remain to be confirmed.  
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1.3 GLP-1 IN OBESITY, INSULIN RESISTANCE, TCF7L2 
POLYMORPHISMS AND TYPE 2 DIABETES 
Attempts to identify genes predisposing for T2D have shown a strong 
association between the transcription factor 7-like 2 (TCF7L2) rs7903146T 
allele and T2D, independent of ethnicity [54-55]. Further studies have 
revealed defective insulin secretion following oral glucose tolerance test 
(OGTT), but not following i.v. glucose challenge, in carriers of this allele 
[56]. The differential effects of orally and i.v. administered glucose 
provoked assessment of incretin-induced insulin secretion in patients with 
variants in the TCF7L2 gene. Resulting data support impaired GLP-1-
induced insulin secretion with variants of TCF7L2, resulting from a 
functional defect in the GLP-1 signaling in β-cells - rather than defect GLP-
1 secretion [56].  
However, defects in the response to GLP-1 are not generally associated with 
T2D [57], and further studies are necessary to rule out involvement of other 
stimuli -- such as GIP [58] -- and confirm a potential specific defect in β-cell 
GLP-1 signaling with TCF7L2 variants and the central role of GLP-1 in the 
pathophysiology of T2D that this would infer.  
In addition, defective GLP-1 secretion has been reported in T2D [59-61], 
indicated to result from defective secretion of the hormone and not from a 
transcriptional defect, as increased intestinal proglucagon mRNA has been 
observed [62] [63]. However, some studies have failed to show defective 
GLP-1 secretion in T2D, and a generalized association of defective GLP-1 
secretion and T2D as such cannot be made [64]. 
The strong co-morbidity of obesity and T2D has led to studies on effects of 
TCF7L2 polymorphisms on obesity. Such studies reveal that TCF7L2 is not 
a risk factor for obesity, but obesity modifies the risk that TCF7L2 variants 
confer [65]. Although different variants of TCF7L2 display differential 
patterns of association with BMI, rs7903146T was associated with a higher 
risk for T2D in non-obese subjects [65-66], suggesting that the mechanisms 
for glucose intolerance are different in severe obesity. 
Decreased levels of circulating GLP-1 in response to meal ingestion have 
been linked to impaired glucose tolerance (IGT) [67-68] and increasing BMI 
[67]. Further, decreased GLP-1 levels have been observed with increased 
BMI and obesity in patients with or without T2D [69], where defective 
GLP-1 secretion has also been correlated to insulin resistance [70]. These 
data are further supported by the observation of defective GLP-1 secretion 
in T2D but not in type 1 diabetes [71].  
Whether defective GLP-1 secretion in obesity overshadows indicated 
TCF7L2-associated defective GLP-1 signaling, and differences in BMI 
contribute to discrepancies between different studies of GLP-1 
secretion/signaling, TCF7L2 polymorphisms and T2D is not known. 
GLP-1 administration to patients with T2D may completely normalize 
hyperglycemia with the avoidance of hypoglycemia regardless of the GLP-1 
dose administered due to the dual glucose-dependency of GLP-1 action on 
both insulin and glucagon secretion [20].  
 
1.4 GLP-1 SYNTHESIS, SECRETION AND DEGRADATION 
GLP-1 is produced by posttranslational cleavage of proglucagon. Available 
evidence suggests that only one proglucagon gene is expressed in mammals 
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giving rise to an identical mRNA in brain, pancreas, and intestine [72]. 
Tissue-specific posttranslational cleavage of proglucagon gives rise to five 
distinct peptides: Glucagon in the pancreatic α-cells -- although there are 
reports indicating a low expression of prohormone convertase 1 (PC1) and 
GLP-1 secretion also from pancreatic α-cells [73] --, glicentin, 
oxyntomodulin, GLP-1 and GLP-2 in the intestine, while GLP-1 also is 
secreted in parts of the CNS. GLP-1 in the enteroendocrine L-cells results 
from proglucagon processing by the prohormone convertase PC1/3. Further, 
there is evidence for cell type-specific regulation of proglucagon gene 
expression mediated by the Wnt signaling pathway. Specifically, Wnt 
signaling regulates proglucagon expression in intestinal GLP-1-secreting 
cells, but not in pancreatic glucagon-producing cells. Interestingly, the T2D 
risk gene TCF7L2 is an effector of the Wnt signaling pathway and thus 
controls transcription of the proglucagon gene in L-cell lines [74-75]. In 
addition, knockdown of TCF7L2 in cells expressing the proglucagon gene 
reduced intestinal glucagon gene expression and glucose-induced insulin 
secretion in mice [74]. These mice also displayed defective glucose 
homeostasis; however, no effect on pancreatic glucagon gene expression was 
detected [74]. 
 
Plasma GLP-1 levels rise within 10–15 min of food ingestion and reach peak 
levels of 15–50 pmol/l by 40 min [76]. Further, GLP-1 -- like insulin -- is 
secreted in a pulsatile manner with a frequency comparable to that of 
pancreatic hormones [77]. 
 
1.4.1 Nutrient-stimulated secretion 
GLP-1 is secreted in a nutrient-dependent manner [78], where GLP-1 
secretion is responsive not only to metabolizable sugars (glucose or fructose) 
and nonmetabolizable monosaccharides [79-80], but also to proteins and fats. 
The mechanisms of GLP-1 secretion has been investigated using different cell 
lines, and is indicated to involve membrane depolarization resulting in the 
opening of voltage-gated Ca2+ channels, where the resulting elevated Ca2+ 
concentrations stimulate secretion of GLP-1.  
Glucose stimulates GLP-1 secretion in rodents and human subjects when 
given orally but systemic hyperglycemia does not activate L-cell secretion. 
It is indicated that L-cell glucose sensing is complex and involves several 
glucose-sensing mechanisms that work synergistically to define the glucose 
response, as reviewed in [81].  
The intestinal L-cells express the KATP channel subunits and glucokinase is 
expressed in murine L-cells [82-84]. Further, the facilitative glucose 
transporter GLUT-2 plays a role in basolateral glucose flux in small 
intestinal epithelial cells, and if similarly expressed in L-cells could provide 
both a glucose efflux pathway and a potential means of responding to 
changes in glycemia [85]. However, the EC50 of glucose-induced GLP-1 
secretion in models of the L-cells (0.2–0.5 mmol/l) differ substantially from 
the half-maximally effective substrate concentration of glucokinase (S0.5 ׽8 
mmol/l) [86]. Another possible mechanism of glucose response is through 
sodium–glucose transporter (SGLT) activity [87]. SGLTs are expressed in 
L-cells and use an inwardly directed sodium gradient to facilitate glucose 
uptake into the cells, even at low luminal glucose concentrations. Using cell 
line models of L-cells, it has been shown that the electrogenic activity of 
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SGLT-1 is sufficient for membrane depolarization and GLP-1 release. There 
is, however, also evidence for the expression of sweet taste receptors [88] in 
intestinal endocrine cells. The effects of ligands for sweet taste receptors, 
such as artificial sweeteners, on GLP-1 secretion are still debated. However, 
there is data in support of a glucose responsiveness regulated by sweet taste 
receptors, where the activation of sweet taste receptors may alter SGLT 
expression [81, 89].  
The mechanism of protein-triggered GLP-1 release remains unclear, but it 
has been reproduced by peptones [90-92], as well as by amino acids [93-
94]. 
Fatty acids stimulate GLP-1 release in human subjects by enteral 
stimulation, whereas increased plasma levels of free fatty acids do not alter 
secretory response from GLP-1-secreting cells [95-96]. However, different 
types of fat differ in their ability to stimulate GLP-1 release, where saturated 
fatty acids induce a higher increase in plasma triacylglycerol but lower 
GLP-1 secretory response [97]. The molecular mechanisms linking fatty 
acids to GLP-1 secretion are not fully understood. However, short chain 
fatty acids (SCFAs) and SCFA receptors as well as G protein-coupled 
receptors (GPCR) are involved in mediating fatty acid-induced GLP-1 
secretion [98-100].  
GPR40, GPR119 and GPR120 are GPCRs that have fatty acids as ligands 
and are indicated to be involved in the fatty acid-induced GLP-1 secretion 
[100-101].  
GPR40 and GPR119 are abundantly expressed in the human pancreas and 
gastrointestinal tract, and have attracted considerable interest as T2D drug 
targets in the past few years, as specific agonists for GPR40 and GPR119 
have been demonstrated to mediate dual elevation of both insulin and GLP-
1. Specifically, activation of GPR119 causes intracellular accumulation of 
cAMP, and enhanced glucose-dependent secretion of both insulin and GLP-1, 
and GPR40 is coupled to Gq and results in PKC- and inositol-1,4,5-
trisphosphate-dependent Ca2+ release inducing insulin and GLP-1 secretion 
[102-117]. Interestingly, GPR40 and GPR119 agonists show promising 
antidiabetic effects in clinical trials [118-119]. 
GPR120 is expressed in L-cells and has been shown to mediate GLP-1 
release in vitro [99]. 
However, there may be additional fatty acid-responsive pathways. 
Specifically, uncoupling protein 2 (UCP2),  regulating the production of 
reactive oxygen species (ROS), is indicated to mediate GLP-1 secretion 
following acute exposure to fatty acids [120]. Interestingly, however, UCP2 
expression exerts opposing actions on glucose-induced GLP-1 secretion, 
where an inhibitory role has been suggested [121]. 
 
1.4.2 Neural and hormonal regulation of GLP-1 secretion 
Hormonal and neuronal signals enhance secretion downstream of membrane 
depolarization by increasing cAMP production or triggering Ca2+ release from 
intracellular stores [122-124]. There is also evidence that direct cholinergic 
muscarinic control of the L-cells regulates the pulsatility of GLP-1 secretion 
[77]. 
Whether the L-cell density is high enough in the upper intestine for direct 
nutrient stimulation to account for the acute phase of GLP-1 secretion is 
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debated. However, there is clearly -- in addition to direct nutrient stimulation -
- also a neural and hormonal regulation of GLP-1 secretion, as illustrated by 
the presence of a proximal–distal loop, involving nutrient detectors located in 
upper regions of the GI tract controlling release of GLP-1 from distal L-cells, 
as well as by the importance of the vagus nerve for GLP-1 secretion [125]. 
 
In addition, there is evidence for cephalic GLP-1 secretion with subsequent 
insulin secretion resulting from meal anticipation [126]. However, other 
studies demonstrate that insulin levels increase rapidly after meal ingestion, 
and before an increase in GLP-1 levels can be detected [127].  
 
1.4.3 Additional regulators of GLP-1 secretion 
Studies using GLP-1-secreting cell lines have demonstrated that bile acids 
promote GLP-1 secretion through a G protein-coupled bile acid receptor 
(TGR5), where the stimulation of GLP-1 secretion is cAMP-dependent 
[128-129]. Subsequent studies have also demonstrated that TGR5 agonists 
increase GLP-1 secretion and improve glucose homeostasis in mice [130-
132]. Further, peroxisome proliferator-activated receptor (PPAR) β/δ 
activation increases proglucagon expression and enhances bile acid-induced 
GLP-1 secretion by L-cells in vitro and ex vivo in human jejunum [133]. 
 
Progesterone was very recently identified as yet another regulator of GLP-1 
secretion. Progesterone increased GLP-1 secretion from an L-cell line and 
enteral progesterone administration increased plasma levels of GLP-1, GIP, 
and insulin, while improving oral glucose tolerance independent of the 
classical progesterone receptor. Further, this effect of enteral progesterone 
was indicated to be independent of classical incretin receptor signaling and 
preserved in glp1r-/- and glp1r-/-:gipr-/- mice [134].  
 
 
 
 
Figure 1: Simplified illustration of the intestinal L-cells’ unique environment, allowing for 
direct nutrient sensing as well as neuronal and hormonal stimulation. See text for details. 
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1.4.4 Degradation 
Native GLP-1 has a half life of less than 2 minutes, due to rapid degradation 
by dipeptidyl peptidase-4 (DPP-4, a.k.a. CD26) ubiquitously present in 
plasma, and this complicates its application as an antidiabetic drug. In fact, > 
80 % of GLP-1 is degraded between secretion and post-hepatic passage. DPP-
4 is a peptidase existing both as a soluble form present in plasma and as a 
membrane-associated form expressed on the cell surface of many cell types, 
including intestinal cells. DPP-4 cleaves proteins with an N-terminal proline 
or alanine at position 2, rendering GLP-1 with alanine at this position an 
ideal substrate. The cleavage of GLP-1 generates an NH2-terminally 
truncated (9-36) metabolite in addition to renal excretion. Stable GLP-1 
analogs and DPP-4 inhibitors are available as diabetes therapy. However, 
enhancing endogenous GLP-1 production may be more physiological as it 
allows also for portal signaling of GLP-1. 
 
 
1.5 THE INTESTINAL EPITHELIUM 
1.5.1 Morphology  
The gastrointestinal (GI) tract is divided into the small and large intestine, 
where the cecum is considered to identify the beginning of the large 
intestine. The small intestine is further divided into three structural parts: the 
duodenum, jejunum and ileum. The majority of GLP-1-secreting L-cells are 
located in the distal gut, predominantly in the ileum and colon.  
Digested food passes through and is absorbed from the intestinal cavity or 
the so called lumen. Going from the lumen and radially outward, the 
epithelium containing myofibroblasts, blood vessels, and nerves is followed 
by the muscularis mucosa and the muscular external, which are two layers 
of smooth muscle. Lastly there is the serosa which is made up of loose 
connective tissue and coated in mucus to prevent friction damage from the 
intestine rubbing against other tissue.  
 
 
 
Figure 2. Image showing GLP-1-positive cells migrating from the intestinal crypts up the 
intestinal villi. Illustrated to the left is how the mouse intestinal sample was prepared to 
generate the morphology of the section presented to the right. The sample was cut open 
from the distal to the proximal end and rolled to have the luminal side with protruding villi 
facing the center of the roll. The samples were then section as illustrated. 
Smooth 
muscle
Villi
GLP-1 
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1.5.2 The L-cells 
Along the whole length of the GI tract in the epithelium are specialized 
cells, including goblet cells, but also specialized enteroendocrine cells such 
as the GLP-1-secreting L-cells and the GIP-secreting K-cells. The mucosa 
and epithelium of the intestinal wall forms finger-like protrusions called 
villi that increase the surface area. The adult mouse intestinal epithelium 
undergoes continuous renewal, which takes place in these villi, and the 
crypts that surround the base of each villus. L-cells originate from 
progenitor cells in the crypts – data support the presence of specific 
progenitors for the L-cell lineage in the intestinal crypts and the 
involvement of GLP-1 signaling in the proliferation of these precursor cells 
[135]. The L-cells differentiate as they migrate up the villus, before 
eventually being shed off the villus tip [136-137]. The origin of 
enteroendocrine cell lineages is not fully understood, but studies support the 
idea of a multipotent endocrine stem cell giving rise to multiple lineages 
[137]. Situated on the villi lining the intestine the L-cells have apical 
microvilli facing the gut lumen and secretory vesicles located adjacent to the 
basolateral membrane. This morphology also makes it possible for the L-
cells to be regulated by neuronal factors and hormones, as well as by direct 
nutrient stimulation [79, 81].  
 
1.6 GLUTAG CELLS AND GLP-1 SECRETION 
Preparations of adult L-cells enriched by elutriation or derived by fetal rat 
intestinal culture might theoretically be superior to cell lines for studies of 
GLP-1 release, because they are not immortalized. However, because they 
contain, at best, only ~ 10 % L-cells, they are inappropriate for single-cell 
studies. GLUTag cells are a stable immortalized murine enteroendocrine cell 
line that expresses the proglucagon gene and secretes GLP-1. This cell line 
was isolated from a glucagon-producing enteroendocrine cell tumor that arose 
in glucagon gene-SV40 T antigen transgenic mice [138] and provides a 
homogenous population of enteroendocrine cells. They are electrically 
excitable cells that depolarize and fire action potentials in response to a range 
of nutrients, including monosaccharides and amino acids. Nutrients trigger 
membrane depolarization and the opening of voltage-gated Ca2+ channels and 
an elevation of intracellular Ca2+, necessary for the stimulation of GLP-1 
release [124]. Further, peptides or pharmacological agents that increase 
cyclic AMP also increase levels of intracellular Ca2+ in GLUTag cells and 
thereby stimulate GLP-1 secretion [124, 139]. GLUTag cells have been 
propagated since 1991, and early passage cells have retained a well 
differentiated phenotype indicated by a responsiveness to physiological and 
pharmacological secretagogues that is very similar to that of primary rat 
intestinal cell cultures [123, 140]. GLUTag cells display a pattern of 
receptor-, ion channel- and glucose sensor-expression that is very similar to 
primary murine L-cells [84]. In addition, signal transduction pathways that 
operate in GLUTag cells are very similar to those operating in primary 
murine L-cells, and GLUTag cells even display a very similar EC50 for 
glucose-stimulated GLP-1 secretion [84].  
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However, one major general drawback of in vitro studies of L-cells is the 
inability to assess effects of apical vs. basolateral stimulation with agents. 
 
1.7 DIABETIC HYPERLIPIDEMIA AND LIPOTOXICITY 
T2D, characterized by chronic insulin resistance and a progressive decline 
in β-cell function [141], may be considered a lipid disorder as well as a 
disease of dysregulated glycemia [142], as obesity (defined as body mass 
index [BMI] > 30) is a major risk factor for the development of T2D [143], 
and obesity and T2D are associated with hyperlipidemia or increased 
circulating concentrations of free fatty acids (FFA) [144-146]. The elevated 
FFA concentrations have been shown to result from increased release of 
FFAs from adipose tissue, where this increased lipolysis is linked to 
adipocyte size. As insulin decreases lipolysis and increases glycerol and 
fatty acid synthesis, insulin resistance will lead to increased lipolysis. The 
high levels of FFAs induce insulin resistance and are toxic to many cell types, 
including the insulin-secreting β-cells - where impaired β-cell function and 
decreased viability is observed following long term FFA exposure [147]. 
Normal circulating FFA levels are approximately 0.5 mmol/l [148]. 
Differential pathological processes have been suggested to underlie the toxic 
effects of sustained hyperlipidemia. FFAs enter cells mainly through fatty 
acid transporters, such as CD36/FAT, and FATPs [149-150]. However, fatty 
acids can also diffuse across or acts as ligands for G protein-coupled receptors 
on the cell surface. Once inside the cell, fatty acids can be esterified, 
metabolized to lipid second messengers, or β-oxidized in the mitochondria. 
The mechanisms behind the metabolic fate of FFAs taken up into the cells are 
incompletely understood. However, the type of FFA, exposure time and 
energy demand of the tissue are of importance [151-153]. AMP-dependent 
protein kinase (AMPK) activation plays a major role in fatty acid β-
oxidation and fatty acid synthesis by phosphorylating and inhibiting the 
enzyme acetyl-CoA carboxylase (ACC). ACC catalyzes carboxylation of 
acetyl-CoA producing malonyl-CoA, which is used as a substrate for fatty 
acid biosynthesis, and a potent inhibitor of mitochondrial fatty acid uptake 
secondary to inhibition of carnitine palmitoyltransferase 1 (CPT1) [153]. 
The accumulation of fatty acids as triglycerides in nonadipose tissue 
(steatosis), seen in hyperlipidemia, is associated with impaired insulin 
signaling and lipotoxicity [154]. However, although non-adipose tissue 
accumulation of triglycerides is an indicator of lipid overload and 
hyperlipidemia in humans and animal models, triglyceride accumulation in 
tissue and triglycerides themselves are most likely inert in terms of 
lipotoxicity [152, 155]. Rather, it is FFAs channeled to other metabolic fates, 
such as production of ROS or ceramide, which mediate the lipotoxic effects.  
 
1.7.1 ROS production  
De novo ceramide production, as well as increased production of ROS 
resulting from increased β-oxidation, has been implicated in lipotoxic effects 
in insulin-secreting β-cells [156-160]. ROS are chemically reactive 
molecules containing oxygen, such as oxygen ions and peroxides. ROS are 
natural byproducts of the normal metabolism of oxygen. However, during 
times of environmental/metabolic stress, ROS levels can increase 
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dramatically, which may result in significant damage to cell structures. 
Apoptosis signal-regulating kinase 1 (ASK1) is a member of the MAP 
kinase kinase kinase family and a part of the MAP kinase signaling 
pathway. When cells are exposed to oxidative stress, such as ROS, the ASK1-
interacting molecule thioredoxin dissociates from ASK1. This converts 
oxidative stress to a phosphorylation-dependent signal where ASK1 
phosphorylates downstream substrates, such as c-Jun N-terminal kinase 
(JNK) and p38 mitogen-activated protein kinases, mediating cellular 
dysfunction and apoptosis [161-162].  
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Figure 3. Simplified scheme of ROS-mediated phosphorylation signaling in induced 
cytotoxicity. See text for details. 
 
 
1.8 DIABETES THERAPY  
 
1.8.1 Lifestyle intervention  
Body weight loss and modifications in food intake result in decreased lipid 
levels and inflammatory activity. Regular exercise and/or dietary modification 
-- even without weight loss -- can improve insulin sensitivity, and dietary 
caloric restriction alone normalizes β-cell function and hepatic insulin 
sensitivity. In addition, the progression into overt diabetes can be prevented 
by moderate lifestyle changes in individuals with IGT [163]. 
 
1.8.2 Sulfonylureas 
Sulfonylureas are a class of drugs that act by increasing insulin release from 
the β-cells and do so irrespective of ambient glycemia. The main target of 
action of sulfonylureas is the SUR/Kir 6.2 subunit of the ATP-dependent 
potassium channel (KATP) found in many cell types, including the insulin 
secreting β-cells, cardiomyocytes and GLP-1-secreting L-cells. The binding 
of sulfonylureas to the KATP channel on the β-cells mediates closure of the 
channel, inhibited efflux of potassium and membrane depolarization with 
the subsequent opening of voltage-gated Ca2+ channels and insulin 
secretion. However, despite the presence of KATP channels on GLP-1-
secreting cells, sulfonylureas have not been shown to stimulate GLP-1 release 
in humans [79]. 
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1.8.3 Metformin 
Metformin is an oral, anti-diabetic, cationic drug of the biguanide class and 
the most widely prescribed anti-diabetic agent in the world. Intestinal 
absorption of metformin involves an active, saturable uptake process, where 
metformin has been shown to be transported by the human organic cation 
transporters 1 (OCT-1), and the proton-activated organic cation transporter, 
plasma membrane monoamine transporter (PMAT). 
Metformin is a first-line drug in the management of T2D and frequently 
prescribed if set glycemic goals for lifestyle changes are not reached within 1-
3 months. Metformin reduces blood glucose by direct effects on the liver and 
reduced gluconeogenesis as well as reduced insulin resistance. The 
mechanisms behind the anti-diabetic actions of metformin are still unclear, 
although the best known target for metformin is the 5' AMP-activated protein 
kinase (AMPK) - a fuel and stress-sensing enzyme that is considered a master 
switch of glucose and lipid metabolism in various organs [164]. Metformin 
has been shown to protect isolated islets from lipotoxicity [165]. Metformin 
treatment of non-diabetic patients is associated with increased levels of 
circulating GLP-1 following an oral glucose load [166], as well as additive 
glucose-lowering benefits in diabetic subjects following GLP-1-based therapy 
[167]. Recent reports also indicate increased GLP-1R expression in pancreatic 
islets in response to metformin treatment [168]. The mechanisms behind 
metformin-induced increases in plasma GLP-1 levels are largely unknown, 
but have been suggested to result from inhibited enzymatic degradation of 
GLP-1 [166], although several studies show no effect of metformin on GLP-1 
degradation [169-170] as well as additive effects on plasma GLP-1 in 
response to  metformin and a DPP-4 inhibitor [171]. The acute stimulation 
of GLP-1 secretion by metformin in rats has been suggested to be indirect, 
requiring M3 muscarinic receptors and gastrin-releasing peptide (GRP) 
[172].  
 
1.8.4 Insulin 
As T2D progresses, insulin replacement therapy oftentimes eventually 
becomes necessary. Insulin has been shown to acutely stimulate GLP-1 
secretion, through PI3K activity, in L-cell models and fetal rat intestinal cells 
[173]. 
 
1.8.5 Exendin-4 and incretin agonists 
Exendin-4, a 39-amino acid peptide hormone, was found in the venom of the 
Gila monster (Heloderma suspectum) and it is a high-affinity agonist of 
mammalian GLP-1R. It shares 53 % of its amino acid sequence with that of 
native GLP-1. Exendin-4 displays biological properties similar to GLP-1 as a 
regulator of glucose metabolism and insulin secretion. Unlike GLP-1, 
exendin-4 has a much longer half-life (60-90 min) and therefore is currently 
used in the management of T2D. Since 2007 it is registered in EU against 
T2D and is available in European pharmacies under the brand name Byetta. 
Long-acting exendin-4 (Bydureon) has also recently been made available for 
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once weekly dosing. Liraglutide (brand name Victoza) is another GLP-1 
analog with 97 % homology to the native peptide, which contains an arginine 
35 lysine substitution, a glutamine substitution and a FFA addition to lysine. 
The FFA addition greatly increases liraglutide binding to albumin, resulting in 
a plasma half-life of 10-14 hours after s.c. injection [174]. Liraglutide can be 
administered once daily and reduces both fasting and postprandial glycemia.  
Lixisenatide (brand name Lyxumia) is another GLP-1R agonist in late-stage 
development. The half-life of lixisenatide is 2-4 hours. Despite its short half-
life, lixisenatide is intended for once daily dosing due to its strong affinity for 
the GLP-1R. Lixisenatide has been shown to have beneficial effects on HbA1c 
and good prandial coverage in combination with other commonly used oral 
agents for T2D, with no increased risk of hypoglycemia [175]. 
 
1.8.6 DPP-4 inhibitors 
Another approach to increase/normalize serum levels of GLP-1 is to prevent 
its breakdown by employing inhibitors of DPP-4. One such drug, sitagliptin, 
was approved in EU in 2007 against T2D and is available in pharmacies 
under the name Januvia. However, recent reports indicate that sitagliptin 
may also exert direct -- DPP-4-independent -- effects on intestinal L-cells, 
activating cAMP and ERK1/2 signaling and stimulating total GLP-1 
secretion [176]. Other recently launched or approved DPP-4 inhibitors 
include vildagliptin (Galvus), saxagliptin (Onglyza), alogliptin (Nesina) and 
linagliptin (Trajenta). Most of the DPP-4 inhibitors are structurally distinct. 
Alogliptin is a quinazolinone-based compound, linagliptin is a xanthine 
derivative, saxagliptin is a hydroxyadamantyl compound, sitagliptin is a 
triazole-pyrazine compound, and vildagliptin is a pyrrolidine-carbo-nitrile 
compound.  
 
1.8.7 α-glucosidase inhibitors 
α-glucosidase inhibitors, such as acarbose, miglitol and voglibose, are 
saccharides that act as competitive inhibitors of pancreatic α-amylase and 
intestinal brush border α-glucosidases producing a delayed hydrolysis of 
ingested polysaccharides, oligosaccharides and disaccharides to 
monosaccharide. Consequently, less glucose is absorbed and the 
postprandial rise in plasma glucose is blunted. Studies have shown that α-
glucosidase inhibitors increase postprandial levels of GLP-1 in normal and 
diabetic subjects - most likely due to reduced carbohydrate absorption in the 
proximal part of the intestine, which increases the load of these nutrients in 
the distal intestine where the secretion of GLP-1 is greater [177-179]. 
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2 AIMS 
The over-arching aim of this work was to investigate effects of diabetic 
lipotoxicity and commonly prescribed anti-diabetic agents on growth, 
viability and function of GLP-1-secreting cells, in an attempt to also unravel 
some of the mechanisms regulating these enteroendocrine cells. The ultimate 
aims were to gain pathogenic understanding of the impaired incretin response 
characterizing T2D patients and to identify potentially druggable targets and 
pathways for therapeutic efforts to enhance GLP-1 production in a 
physiologic way. 
 
 
More specifically the aims were: 
 
• To determine whether metformin exerts direct long-term effects on 
the regulation of GLP-1-secreting cells in terms of apoptosis and 
secretion, the nature of such effects, and the possible involvement of 
AMPK.  
 
• To determine the molecular mechanisms mediating lipotoxicity, and 
metformin-induced lipoprotection, in GLP-1-secreting cells.  
 
• To investigate the effect of insulin signaling as well as possible 
autocrine action of GLP-1 on apoptosis and function of the GLP-1-
secreting cells.  
 
• To determine the effects of a high fat diet on the number of 
enteroendocrine GLP-1-secreting cells and GLP-1 plasma levels in a 
rodent model, and possible effects of metformin treatment on these 
parameters. 
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3 MATERIALS AND METHODS 
This study was initiated as a scanning study encompassing a large number of 
anti-diabetic agents and hormones that were scanned for direct effects on the 
proliferation, apoptosis and function of GLP-1-secreting cells using in vitro 
incubations of GLUTag cells with or without the different agents. In addition, 
these agents were evaluated for effects also in the presence of simulated 
diabetic hyperglycemia/hyperlipidemia. This scanning study remains to be 
published as such.  
The present thesis focuses on the effects observed in response to metformin, 
exendin-4, and insulin.  
  
3.1 STUDY PROTOCOLS 
3.1.1 Cell culture and incubation (study I-III) 
The GLP-1-secreting GLUTag cell line (source: glucagon-producing 
enteroendocrine cell tumor that arose in transgenic mice generated on an out-
bred CD-1 background) [138], graciously donated by Dr. Neil Portwood at 
Karolinska Institutet, Solna, Sweden, and originally from Dr. Daniel J. 
Drucker, Mount Sinai Hospital, Samuel Lunenfeld Research Institute, 
University of Toronto, Canada, was cultured in DMEM supplemented with 
10 % fetal bovine serum (FBS), 5.5 mmol/l glucose, 10,000 U/ml penicillin 
and 10 mg/ml streptomycin sulfate under 5 % CO2. Palmitate exposure media 
were supplemented with 2 % FBS and 0.5 % bovine serum albumin (BSA). 
Palmitate was dissolved in 12.5 % ethanol during heating to 60 ºC. Control 
cells were given vehicle with equal amounts of ethanol as the palmitate 
exposed cells (final concentration of ethanol: 0.03 %). 
 
3.1.2 Western blot (study I-II) 
Western blotting was applied to quantify total and phosphorylated ACC, 
AMPK, JNK (Study I), and p38 (Study II) following culture w/wo agents in 
the presence or absence of palmitate-albumin complex at 2 % serum DMEM. 
GLUTag cellular protein was extracted, using RIPA lysis buffer, for 30 min 
on ice. Cells were sonicated and lysates were cleared by centrifugation. 
Protein concentration was determined and cell extracts were stored at -80 ºC. 
Equal amounts of protein were then mixed with reducing SDS-PAGE sample 
buffer, boiled for 5 min and proteins separated by SDS-PAGE. Samples 
containing 25-30 µg of protein were electrophoresed against a pre-stained 
protein ladder on a 10-12 % polyacrylamide gel under denaturing conditions, 
followed by transfer to PVDF membrane. Membranes were blocked with 5 % 
milk solids in PBST; primary (overnight) and secondary (1 h) antibody 
incubations were performed in the same buffer, with three 10-min washes in 
PBS-T intervening.  
Horseradish peroxidase-conjugated secondary antibodies (1:5,000) and ECL 
(enhanced chemiluminescence) reagents were used to detect proteins. Images 
and quantifications were obtained using Molecular Imager ChemiDoc XRS 
with Quantity One Software (v. 4.6.5). After imaging, the PVDF membranes 
were stained with Coomassie Brilliant Blue for total protein normalization. 
Phosphorylation was determined after normalization with total 
 25 
 
(phosphorylated and non-phosphorylated) forms of the protein or α-
tubulin/Coomassie staining. 
 
3.1.3 MTT assay (study I) 
The MTT assay was used to determine the number of viable cells after 
treatment with/without palmitate. GLUTag cells were plated and cultured in 
96-well plates at a density of 136,000 cells/ml for 24 h. Cells were then 
washed and treated with or without 0.125 mmol/l palmitate for 48 h in the 
presence of low serum medium (2 % FBS). Viable cell densities were 
determined by metabolic conversion of the dye MTT. 15 µl of the supplied 
MTT solution was added to each well and the plates were then incubated for 
an additional 4 h. The MTT reaction was terminated by the addition of 100 μl 
acidified isopropanol, dissolving the formazon product formed. After 1-2 h at 
4 ºC, MTT assay results were read by measuring absorption at 540 nm.  
 
3.1.4 Protein assay (study I-III) 
GLUTag cells were washed twice with phosphate buffered saline (PBS) and 
lysed on ice in a RIPA lysis buffer containing 150 mmol/l NaCl, 20 mmol/l 
Tris, 0.1 % SDS, 1 % Triton X-100, 0.25 % Na-deoxycholate, 1 mmol/l 
Na3VO4, 50 mmol/l NaF, 2 mmol/l EDTA and Protease inhibitory cocktail 
(Sigma-Aldrich) for 30 min. Samples were clarified by centrifugation, 
supernatants were transferred to new tubes and the total protein concentration 
was determined with Bio-Rad DC protein assay (method of Lowry [180]), 
using BSA as a standard (Bio-Rad Laboratories, Hercules, CA).  
 
3.1.5 Apoptosis assays (study I-III) 
3.1.5.1 DNA fragmentation ELISA (study I) 
GLUTag cells were plated at a density of 180,000 cells/ml and grown in 24-
well plates for 24 h. Cells were then washed twice with low serum medium (2 
% FBS, 5.5 mmol/l glucose) and then treated with metformin at indicated 
doses in 2 % FBS and 5.5 mmol/l glucose medium for an additional 48 h. 
DNA fragmentation ELISA (Roche Diagnostics GmbH, Mannheim, 
Germany) was used according to the manufacturer's instructions. Briefly, the 
cells were lysed and lysates and reagents were added as described by the 
manufacturer and the ELISA plate was read by measuring absorption at 450 
nm. All experiments were performed in triplicates and repeated twice to 
assess consistency of response. 
 
3.1.5.2 Caspase-3 activity assay (study I-III)  
GLUTag cells were plated at a density of 250,000 cells/ml and grown in Ø60 
mm Petri dishes for 24 h. Cells were then washed twice with low serum 
medium (2 % FBS, 5.5 mmol/l glucose) and then treated with metformin 
(study I), Trolox (study II), exendin-4/insulin (study III) at indicated doses in 
2 % FBS and 5.5 mmol/l glucose with 0.125 mmol/l palmitate/vehicle for an 
additional 48 h. Caspase-3 activity assay kit (Cell Signaling Technology, Inc., 
Danvers, MA) was used according to the manufacturer's instructions. Briefly, 
the caspase-3 colorimetric assay is based on the hydrolysis of a substrate by 
caspase-3, resulting in the release of fluorescent product, which can be 
measured at 405 nm. 
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3.1.6 GLP-1 secretion and ELISA (study I and III) 
Long term: GLUTag cells were plated at a density of 180,000 cells/ml and 
grown in 24-well plates for 24-48 h. Cells were then treated with metformin 
(study I) or exendin-4/insulin (study III) at indicated doses for an additional 
48 h. Immediately after the 48 h incubation, medium was collected and DPP-
4 inhibitor added (10 µl/ml) (Millipore Corporation, Billerica, MA).  
Acute: GLUTag cells were plated at a density of 180,000 cells/ml and grown 
in 24-well plates for 24-48 h. The medium was discarded and the cells were 
washed with pre-warmed KRBH buffer/0.2 % BSA/0 mmol/l glucose, 
followed by a 30 min pre-incubation with the same buffer. Cells were then 
treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) (PKC activator), 
forskolin (adenylate cyclase activator) and metformin (study I) or exendin-
4/insulin (study III) for 2 h in the presence or absence of 20 mmol/l glucose. 
Immediately thereafter, DPP-4 inhibitor (Millipore Corporation) was added 
and the buffer was collected. GLP-1 Active ELISA (Millipore Corporation) 
was used according to the manufacturer's instructions.  
 
3.1.7 Quantitative RT-PCR (study I, III) 
Quantitative RT-PCR was used to determine the expression of proglucagon 
mRNA in GLUTag cells (study I) and proglucagon/GLP-1R mRNA in 
intestinal tissue (study IV). GLUTag cells/intestinal tissue samples were lysed 
and RNA extracted using Aurum total RNA mini kit (BioRad Laboratories) 
according to the manufacturer’s instructions. cDNA was synthesized for 
qPCR using iScript™ cDNA synthesis kit (BioRad Laboratories) according to 
the manufacturer’s instructions. 
A one-step RT-PCR kit with SYBR Green (iScript™) (BioRad Laboratories) 
was used for real-time quantitative RT-PCR. This kit utilizes iScript RNase 
H+ reverse transcriptase and hot-start iTaq DNA polymerase. GAPDH was 
used as housekeeping gene for normalization. 
 
3.1.8 Animals and diet (study IV) 
C57/Bl6 mice (Nova/Scanbur, Sollentuna, Sweden) arrived 9 weeks old and 
were housed in our animal department for 1 week prior to initiation of the 
study. Animals were housed in groups of four in a total of eight cages under 
standard laboratory conditions of light, temperature and humidity, and 
received food and water ad libitum. At the initiation of the study, the animals 
were divided into two groups. One group received normal chow 
(Nova/Scanbur) and the other group received the fat-enriched D12492 diet 
consisting of 60% kcal% fat (Research Diets, New Brunswick, NJ). After 10 
weeks on each respective diet, the two groups were each divided into two 
groups of animals where eight animals received oral gavage administration of 
300 mg/day metformin and the remaining eight animals received oral 
administration of saline. 12 weeks after the initiation of the study, animals 
were euthanized using CO2. Throughout the study, weight and food 
consumption for all animals/cages were recorded once a week. 
 
3.1.9 Blood glucose and HbA1c levels (study IV) 
Blood samples for glucose measurements were obtained from each mouse by 
needle puncture of the tail tip vein. Both fasting and prandial glycemia were 
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measured at three time points (before initiation of metformin/saline treatment 
[time 0], 1 week after initiation [time 1] and 2 weeks after initiation before the 
end of the study [time 2]). Blood glucose concentrations were determined by 
means of Bayer's Elite® Glucometer and compatible blood glucose test strips. 
Fasting blood samples for HbA1c measurements were obtained at time 0 and 
time 2 from the same puncture of the tail tip vein. HbA1c was determined 
using a DCA Vantage® Analyzer (Siemens Healthcare Diagnostics, 
Tarrytown, NY) and compatible sample cassettes. 
 
3.1.10 Serum insulin, FFA and GLP-1 determinations (study IV) 
Blood samples were collected from the saphena vein after 6 h fasting at time 
0, 1 and 2 (see above) and transferred to centrifuge tubes at room temperature. 
At time 2, immediately after euthanization, a heart puncture was also 
performed and a larger volume of prandial blood collected. The blood 
samples were spun to obtain serum. The serum was stored in a freezer at -70 
°C for later analysis of insulin, total GLP-1 (7-36 and 9-36), active GLP-1 (7-
36) and FFAs. Serum insulin concentrations were determined using a mouse 
ultrasensitive ELISA (Mercodia, Uppsala, Sweden), according to the 
manufacturer’s instructions. Serum GLP-1 (7-36 and 9-36) and GLP-1 (7-36) 
levels were determined using specific ELISAs (Millipore, Billerica, MA) 
according to the manufacturer’s instructions. Serum FFAs were determined 
using the NEFA-HR(2) assay kit (Wako Chemicals, Richmond, VA) 
according to its instructions. 
 
3.1.11 Oral glucose tolerance test (OGTT) (study IV) 
Food was removed 6 h prior to oral gavage administration of 1.5 g/kg glucose 
at the end of the last week of treatment. At 15, 30 and 60 min following 
administration, blood samples for glucose measurements were obtained from 
each mouse by needle puncture of the tail tip vein. Blood glucose 
concentrations were determined by means of Bayer's Elite® Glucometer and 
compatible blood glucose test strips.   
 
3.1.12 Immunohistochemistry and quantification of L-cells (study IV) 
After euthanization, intestinal tissue was collected from the animals. The 
intestine was extracted and carefully removed of all fat. A 4-cm section 
proximal/distal to the appendix was removed and carefully cut open to have 
the lumen exposed and facing upward. The intestinal tissue section was then 
rolled up, starting with the most proximal end and with the lumen facing the 
center of the roll (technique illustrated in Figure 2). The rolls were attached to 
plastic caps and immediately submerged in a freeze bath of 99 % ethanol and 
dry ice. The rolls were stored in a freezer at -70 ºC pending sectioning of the 
intestinal tissue using a cryostat. The intestinal tissue was sectioned using a 
cryostat in 12 µm thick sections from the top of the roll towards the bottom, 
leaving each section to expose the lumen and villi of the full length of the 
intestinal tissue section. These sections were placed in consecutive order on 
six glass slides starting with position 1 of all slides, followed by position 2 of 
all slides, etc., leaving each and all slides with 10 sections representing the 
full cross section of the lumen. Sections were stored at -70 ºC. 
Prior to IHC, sections were washed in PBS and fixed using a 10 min 
incubation with acetone at -20 ºC. Sections were then washed 3 x 10 min in 
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PBS-T and incubated overnight with a rabbit antibody specific for GLP-1 
(Phoenix Europe GmbH, Karlsruhe, Germany) at 1:500 dilution in PBS-T 
containing 5 % donkey serum. Tissue sections were washed in PBS-T 3 x 10 
min and incubated for 2 h at room temperature in  the dark with the secondary 
antibody (ALEXA Fluor 488 conjugated donkey anti-rabbit) (Invitrogen) at 
1:200 dilution in PBS-T. Sections were washed in PBS 3 x 10 min and 
allowed to dry before a cover glass was mounted using Polyvinyl Alcohol 
mounting medium with DABCO antifading (Fluka Biochemica, 
Ronkonkoma, NY). For the purpose of quantifying cells after IHC, an 
advanced stereology platform, which allows unbiased quantification of cell 
number/volume and structural measurements within the intestinal structure 
[181], was used. 
 
3.1.13 ROS measurement (study II-III) 
GLUTag cells were plated at a density of 300,000 cells/ml and grown in 6-
well plates for 24 h. Cells were then washed twice with low serum medium (2 
% FBS, 5.5 mmol/l glucose) prior to treatment with 0.125 mmol/l palmitate 
and/or 2 mmol/l metformin (study II) or exendin-4 (study III) in 2 % FBS and 
5.5 mmol/l glucose for an additional 24 h. The Image-iTTM LIVE Green ROS 
Detection Kit (Invitrogen, Inc.) used provides the key reagents necessary for 
the detection of ROS in live cells. The assay is based on 5-(and-6)-carboxy-
2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), a reliable 
fluorogenic marker for ROS in live cells.  
 
3.1.14 Statistical analysis (study I-IV) 
Comparisons between groups, treatments and time were made by a one-way 
ANOVA for repeated measures. Comparisons between control and single 
treatment groups were done using two-tailed Student’s t test. Correlations 
were evaluated by determining the Pearson correlation coefficients. P<0.05 
was deemed statistically significant. Power analysis was performed and 
taken into consideration for all experiments.     
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4 RESULTS 
 
4.1 IN VITRO EXPERIMENTS (STUDY I-III) 
4.1.1 Study I 
In study I, we demonstrate that long term exposure to the saturated fatty acid 
palmitate induced lipoapoptosis of the GLP-1-secreting GLUTag cell line. 
Consistent with increased caspase-3 activity in response to palmitate, DNA 
fragmentation increased, while the number of viable cells was significantly 
reduced. We could also demonstrate reduced palmitate-induced caspase-3 
activity and DNA fragmentation in response to co-incubation with metformin 
– indicative of a lipoprotective effect of the drug. Palmitate induced 
phosphorylation of JNK, while metformin phosphorylated AMPK in 
conjunction with a decrease in the palmitate-induced phosphorylation of JNK. 
Further, reduction of palmitate induced phosphorylation of JNK -- using the 
JNK inhibitor SP600125 -- significantly reduced palmitate-induced caspase-3 
activity. The AMPK phosphorylation induced by 2 mmol/l metformin was 
rapidly detectable and sustained for at least 24 h. However, co-incubation 
with the AMPK activator AICAR, or 500 µmol/l metformin, resulted in a 
very rapid and transient phosphorylation of AMPK, while also failing to 
reproduce the lipoprotective effect of metformin. Co-incubation with the 
AMPK inhibitor compound C significantly attenuated the metformin-induced 
reduction of palmitate-induced caspase-3 activity. In study I, we also 
demonstrate reduced expression of proglucagon mRNA, but increased GLP-1 
secretion, following long term exposure to 500 µmol/l metformin. 
 
4.1.2 Study II 
Our results from study II show that palmitate significantly increased ROS 
production, while co-incubation of palmitate with the vitamin E derived 
antioxidant Trolox inhibited the induction of caspase-3 activity. Further, 
palmitate led to phosphorylation of the ROS-sensitive kinase p38, the 
inhibition of which -- using the p38 inhibitor SB203580 -- significantly 
reduced the palmitate-induced caspase-3 activity. We could also demonstrate 
that, although metformin significantly increased ROS production, there was a 
strong down regulation of p38 expression in response to metformin. 
 
4.1.3 Study III 
In this study, we demonstrate expression of the GLP-1R in GLP-1-secreting 
cells, and that GLP-1 secretion was increased in response to treatment with 
exendin-4, an effect that can be detected acutely as well as after more long 
term exposure. Further, the increased GLP-1 secretion following exposure to 
exendin-4 was effectively and significantly blocked by co-incubation with the 
GLP-1R antagonist exendin 9-39. Moreover, we provide evidence for a 
lipoprotective effect of exendin-4 treatment where palmitate-induced ROS 
production and caspase-3 activity were significantly reduced by exendin-4. 
However, co-incubation of palmitate with the PKA activator Sp-cAMP[S] did 
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not reduce caspase-3 activity in response to palmitate. Nor did co-incubation 
with the PKA inhibitor Rp-cAMP[S] significantly alter the reduction of 
palmitate-induced caspase-3 activity seen in response to exendin-4. In this 
study, we also demonstrate that insulin increases secretion of GLP-1 from 
GLUTag cells, again an effect seen acutely as well as after prolonged 
exposure. We also show a reduction of palmitate-induced caspase-3 activity 
in response to co-incubation with insulin. 
 
4.2 IN VIVO EXPERIMENTS (STUDY IV) 
In study IV, we demonstrate that a high fat diet rapidly induced insulin 
resistance and diabetes, with a significant improvement in response to 
metformin, which also was indicated to improve the prandial incretin 
response of HFD-fed mice. However, no significant effect on fasting or 
prandial levels of GLP-1 in response to HFD feeding was detected. Further, 
we provide evidence for a reduced number of intestinal L-cells and 
lipotoxicity in HFD-fed mice, although no significant effect on the intestinal 
proglucagon mRNA expression was detected. We also present data in 
support of increased GLP-1R mRNA expression in HFD-fed mice, an effect 
not observed in HFD-fed mice receiving metformin treatment.  
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5 GENERAL DISCUSSION 
Defective GLP-1 secretion has been observed in T2D patients, and 
administration of GLP-1 can normalize fasting and prandial glycemia. The 
insulin-potentiating actions of GLP-1 have made stable GLP-1 analogs and 
DPP-4 inhibitors among the best anti-diabetic drugs available. However, 
increased endogenous GLP-1 secretion may offer a better and more 
physiological approach for T2D therapy, as endogenous GLP-1 -- unlike 
stable GLP-1 analogs and DPP-4 inhibitors -- is released directly into the 
portal vein prior to hepatic passage. The portal effects of GLP-1 are indicated 
to be of considerable importance, in line with the relatively small portion of 
GLP-1 (7-36)  remaining  post-hepatic passage, including  reports of a GLP-
1-regulated glucose sensor in the portal vein wall that (via nervous signals) 
controls insulin secretion [40]. Further, the liver receives about 75 % of its 
blood through the portal vein, and direct effects of GLP-1 on hepatocytes are 
reported. Further, and in support of the benefits of enhancing the endogenous 
incretin response, the insulinotropic effect of GLP-1 is poorly replicated by 
short-acting GLP-1R agonists, whereas the effect on gastric emptying is lost 
with long-acting GLP-1R agonists – probably due to continuous activation 
and de-sensitization of the GLP-1R [182]. It should also be considered that 
much like other GPCRs, on binding to its ligand, the GLP-1R internalizes 
[183]. This receptor internalization upon ligand binding is seen also with the 
insulin receptor, and much like pulsatile insulin secretion is indicated to 
prevent insulin resistance [184-185], the pulsatile nature of endogenous 
GLP-1 secretion [77] may prevent GLP-1R de-sensitization and GLP-1 
resistance. Consequently, enhancing endogenous GLP-1 secretion provides 
yet another advantage to current incretin therapy. Enhanced endogenous 
GLP-1 secretion can be obtained either acutely by directly stimulating GLP-1 
secretion -- ideally in a nutrient-dependent manner -- or chronically through 
preserving/protecting the native L-cells and thereby obtaining an increased 
secretory capacity through expansion of the L-cell mass. The importance of 
the intestinal L-cell mass for glucose homeostasis has previously been 
demonstrated [186]. 
Understanding what regulates the GLP-1-secreting cells may make it possible 
to modulate the endogenous secretion. In addition, diabetic patients represent 
a selected group that is chronically exposed to certain drugs, the long-term 
effects of which on the intestinal L-cells are unknown. Consequently, the aim 
of this study was to investigate effects of commonly prescribed anti-diabetic 
agents on growth, viability and function of GLP-1-secreting cells, in an 
attempt to also unravel some of the mechanisms regulating these 
enteroendocrine cells. T2D patients often have elevated levels of plasma 
FFAs [144-145], and high levels of FFAs induce insulin resistance and are 
toxic to many cell types. In study I, we demonstrate that palmitate, used to 
simulate hyperlipidemia, induces massive cell death of GLP-1-secreting cells 
in vitro. In this study, we also show -- for the first time -- that the anti-diabetic 
drug metformin has direct long-term effects on the regulation of GLP-1-
secreting cells in vitro, where GLP-1 secretion is induced after long term 
exposure and metformin protects GLP-1-secreting cells from lipotoxicity. 
Study I also attempts to determine some of the molecular mechanisms 
underlying palmitate induced lipotoxicity. JNKs, which are downstream 
components of the mitochondrial death signal [162] and reported to mediate 
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palmitate-induced apoptosis in other cell systems [187], were indicated to 
play a role in mediating lipotoxicity in GLP-1-secreting cells as well. 
Palmitate treatment induced phosphorylation of JNK2, an effect significantly 
attenuated by co-treatment with metformin. Further, the JNK inhibitor 
SP600125 significantly attenuated palmitate-induced caspase-3 activity. 
However, the fact that SP600125 could not, like metformin, completely block 
palmitate-induced caspase-3 activity indicates the involvement of additional 
signaling pathways. The metformin-induced attenuation of JNK activation 
occurred in conjunction with a significant AMPK activation by metformin. 
Differential activation of AMPK in response to 2 mmol/l metformin and 
AICAR/500 µmol/l metformin, where all treatments will induce rapid and 
transient phosphorylation of AMPK but only 2 mmol/l metformin will induce 
a later sustained activation of AMPK, may explain why neither AICAR nor 
500 µmol/l metformin could reproduce the lipoprotective effect of 2 mmol/l 
metformin. The lipoprotective effect of metformin may require a sustained 
activation of AMPK, as also previously reported in other cell systems [188].  
The finding in study I, that co-incubation with the AMPK inhibitor compound 
C resulted in an attenuation of the lipoprotective effect of metformin by 
approximately 50 %, agrees well with the partial (50 %) inhibition of AMPK 
activation achieved by the co-incubation with compound C, and an AMPK 
dependent effect.  
The stimulatory effect of metformin on GLP-1 secretion observed in study I 
indicates differential effects at the transcriptional level and the level of 
translation/secretion, as the same concentration of metformin significantly 
reduced the expression of proglucagon mRNA. Interestingly, PKC is a known 
target of metformin action [189] and activators of PKC have been shown to 
stimulate secretion, but not biosynthesis, of the proglucagon derived peptides 
in GLUTag cell cultures [140]. It may also be that treatment with metformin 
sensitizes the GLUTag cells to GLP-1 secretagogues present in the cell 
culture medium, such as glucose. These are nevertheless pure speculations, 
and further studies are needed to determine the underlying mechanisms. 
However, a stimulatory secretory effect/enhanced nutrient-stimulated 
secretion by metformin would be of potential therapeutic importance since the 
reduced GLP-1 levels seen in T2D patients [60] have been reported to result 
from defective secretion of the hormone and not from a transcriptional defect 
[62] [63].  
In study II, we continue to investigate the mechanisms inducing lipotoxicity 
in the GLP-1-secreting cells in vitro. We first studied ROS production in the 
presence/absence of simulated hyperlipidemia, as increased ROS production 
in response to palmitate has been reported to mediate cell damage and 
apoptosis in insulin-producing β-cells [152, 157]. Study II demonstrates that 
simulated hyperlipidemia increases ROS production and phosphorylates p38, 
where addition of antioxidants or inhibition of p38 can effectively reduce 
lipotoxicity. With an increased ROS production, it is expected to see the 
observed activation of ROS-sensitive pathways (such as ASK1) and 
downstream MKK (such as JNK) -- as demonstrated in study I -- and p38 
phosphorylation demonstrated in study II. It appears that JNK and p38 may 
together be the mediators of lipoapoptosis downstream of increased ROS 
production as the JNK inhibitor SP600125 significantly attenuated palmitate-
induced caspase-3 activity by ~  20 % and p38 inhibition resulted in an ~ 80 
% attenuation of caspase-3 activity. However, pre-incubation of palmitate 
with both inhibitors would be necessary before concluding that these are 
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additive effects, and that inhibiting both kinases will completely block 
palmitate-induced lipotoxicity. In addition, a future goal is to inhibit fatty acid 
oxidation and to determine ROS production and the effect on JNK and p38 
phosphorylation after addition of ROS scavengers, such as SOD and/or 
Trolox.  
Further, we continue to investigate the mechanisms of metformin-conferred 
lipoprotection in study II. Surprisingly, we did not find a decrease in ROS 
production by metformin as observed in rat pancreatic islets and β-cells [190], 
but metformin did significantly reduce the expression of p38 under these 
lipotoxic conditions. The lipoprotective effects of metformin have, in other in 
vitro cell studies, been reported to result from protection against oxidative cell 
injury by induction of a metabolic stress response with stabilization of 
mitochondria whose oxidative capacity is increased [188]. The metformin-
induced increase in ROS production, in conjunction with reduced expression 
of the ROS-sensitive MAPKK p38 shown in study II, may demonstrate a 
metformin lipoprotective effect dependent on increased oxidative capacity 
also in GLP-1-secreting cells.  
In study III, we provide novel data in support of direct effects, modulating 
function and viability, of exendin-4 and insulin -- suggesting stimulatory 
paracrine/autocrine regulation -- on GLP-1-secreting cells. Specifically, our 
data show the expression of the GLP-1R on GLP-1-secreting GLUTag cells 
and also indicate that the GLP-1 mimetic exendin-4 increased GLP-1 
secretion by direct effects on GLP-1-secreting cells. The difficulty in 
obtaining antibodies specific for the GLP-1R should not be ignored, 
wherefore the specificity of the GLP-1R antibody used was confirmed using 
GLP-1R siRNA-transfected GLUTag cells (study III-supplementary data). 
However, contradictory to our findings, lack of GLP-1R expression on 
native murine L-cells was recently reported [135]. The GLP-1R antibody 
used to detect L-cell GLP-1R expression in that particular study may, 
despite demonstrated functionality and specificity in islets, have failed to 
detect intestinal GLP-1R expression due to small tissue specific sequence 
variations / a comparatively very low intestinal expression of the GLP-1R. 
In addition, problems with tissue preparation/intestinal immunostaining 
cannot be excluded, as the same study -- contradictory to known intestinal 
GLP-1R expression [191-192] -- fails to detect any intestinal GLP-1R 
expression, not only L-cell specific. Further, the presence of autocrine 
regulation of glucose-induced GLP-1 secretion -- as reported in the present 
study -- has previously been shown in studies using GLP-1R knockout mice 
[193]. 
Consequently, it remains to be determined whether or not GLP-1R expression 
on GLUTag cells constitutes an important difference from native L-cells, 
rendering autocrine feedback stimulation an in vitro phenomenon. However, a 
positive autocrine feedback of GLP-1R activation in GLP-1-secreting cells 
would be consistent with mechanisms operative in other endocrine cell types, 
e.g. the insulin-producing β-cells [194]. Similar stimulatory effects were 
observed in response to insulin and both agents protected GLP-1-producing 
cells against lipoapoptosis.  
The exendin-4-mediated GLP-1 secretion observed in this study is, as 
expected, GLP-1R-dependent, although mechanistic studies are obviously 
necessary to determine the exact mechanisms behind the observed effects. 
The observed role for insulin in acute glucose-stimulated GLP-1 secretion 
has previously been shown [173]. However, the data from the present study 
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also indicate prolonged stimulatory effects of insulin signaling on GLP-1 
secretion. It should be noted that the glucose-dependent stimulation of GLP-
1 secretion in response to insulin and exendin-4 demonstrated in study III 
indicates that the autocrine/paracrine feed-back loop comes into play only 
when needed. Further, in line with a ROS-induced lipotoxicity as described 
in study II, and exendin-4-mediated lipoprotection, exendin-4 significantly 
reduced palmitate-induced ROS production. Further, the GLP-1R-dependent 
but PKA-independent lipoprotection in response to exendin-4 was expected, 
as previous studies show that exendin-4 reduces ROS independent of PKA 
but dependent of EPAC [36]. Interestingly in this context, increased 
circulating levels of GLP-1 and GLP-1R activation are correlated with an 
increased L-cell number in vivo [135]. 
However, further studies are necessary to confirm the presence of the GLP-
1R on native L-cells and define the intracellular signaling mediating these 
protective/secretory effects, as these studies may help identify molecular 
targets for directly enhancing GLP-1 release/increasing L-cell viability and 
thereby augmenting incretin hormone secretory capacity in T2D. The 
findings in study IV support lipotoxic effects also in vivo, rendering reduced 
number of GLP-1-positive cells detected in the intestinal tissue from HFD-
fed mice as compared to mice receiving control diet. Further, in contrast to 
numerous reports on enhanced GLP-1 secretion in response to dietary fat 
[98, 195], no significant increase in fasting or prandial GLP-1 (7-36 and/or 
9-36) could be detected in our animals chronically fed a HFD. It can be 
hypothesized that the difference lies in the FFA exposure time. While most 
of the studies showing FFA-induced GLP-1 secretion focus on acute effects, 
chronic hyperlipidemia may become toxic to the L-cells and therefore 
eventually impair their secretory capacity rendering no significant 
stimulation as observed in study IV. Such detrimental effects only after 
persistent and long term exposure to hyperlipidemia could theoretically be 
explained by an accumulation of FFAs that eventually exceeds the capacity 
of the L-cell for triglyceride storage and the subsequent increase in β-
oxidation and ROS production as previously reported [152] and indicated in 
study II. The indicated lipotoxicity in study IV is further supported by 
reports on a negative correlation between GLP-1 plasma levels and BMI 
[69]. Animals on a HFD develop hyperglycemia in conjunction with 
hyperlipidemia, as demonstrated in study IV, indicating the manifestation of 
insulin resistance. In study IV, we also demonstrated improved glycemia, 
fasting serum insulin and oral glucose tolerance in response to metformin 
treatment, which was expected and in line with the known anti-diabetic 
properties of metformin. The oral gavage administration did cause nausea 
and reduced food intake during the 14 days of treatment, where those mice 
receiving a HFD displayed significantly reduced appetite. Further, 
metformin treatment initially induced diarrhea. Starting with a lower dosage 
and increasing up to desired dosage over 3-4 days may have avoided this 
side-effect of metformin treatment. To detect if the weight loss during 
treatment was a confounding factor for the beneficial effects of metformin, 
we evaluated weight as an independent parameter for the improved 
metabolic state. The fact that weight alone displayed a significant positive 
correlation with HbA1c, but not fasting serum insulin, indicates that -- 
although the weight loss most likely contributed to the beneficial effects -- 
metformin treatment was indeed effective. Further, the tendency towards 
increased plasma GLP-1 levels in metformin-treated animals on a HFD, 
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despite large individual differences, is interesting in the context of 
metformin-induced lipoprotection in vitro. However, a statistically 
significant effect of metformin on the number of intestinal GLP-1-positive 
cells could not be detected in this study, while reduced intestinal 
proglucagon expression was found. The reduced expression of proglucagon 
agrees well with reduced proglucagon expression in vitro demonstrated in 
study I and indicates metformin stimulatory action to be at the level of 
secretion. However, if metformin treatment also increases the number of 
viable GLP-1-positive cells after a HFD, an increased intestinal proglucagon 
expression would be expected despite possible counteracting effects of 
metformin on proglucagon expression at the level of individual L-cells. It is, 
at this point, impossible to say if these data result from metformin 
lipoprotection being an in vitro phenomenon or a combination of the 
adverse GI side-effects induced by the metformin treatment in this study 
together with the relatively short duration of metformin treatment. The up-
regulation of GLP-1R mRNA in response to a HFD -- and normalization 
thereof by metformin treatment -- provokes further assessment of the 
intestinal expression of the GLP-1R under these conditions. It is, in light of 
a defective incretin response in diabetic patients improved by metformin 
treatment, tempting to hypothesize that compensatory mechanisms underlie 
increased receptor expression in response to reduced levels of the ligand 
and/or defective GLP-1R signaling in HFD-induced T2D.  
In summary, the present study provides evidence for lipotoxicity resulting 
from increased ROS production and downstream activation of MAPKK in 
GLP-1-secreting cells. Further, these studies provide novel and intriguing 
findings suggesting that metformin, exendin-4 and insulin, by direct effects 
on GLP-1-secreting cells, promote secretion and confer protection from 
diabetic lipoapoptosis of these cells. In addition, our findings provide 
evidence for rapid development of insulin resistance and diabetes in mice 
receiving a HFD, with a significant improvement in response to metformin, 
which also was indicated to improve the prandial incretin response of HFD-
fed mice. Further, in line with data from the in vitro studies, we provide 
evidence for reduced L-cell mass and lipotoxicity in HFD-fed mice. 
However, considering the lack of statistically significant effects on fasting 
or prandial levels of GLP-1 in response to HFD, and in line with previous 
reports [196], this proposed lipotoxicity of L-cells seemingly does not 
contribute to the development of oral glucose intolerance, hyperinsulinemia 
or hyperglycemia in this study. It may rather contribute to the progression of 
the diabetic state as it may lead to decreased prandial GLP-1 secretion when 
the reduction of L-cell mass in response to hyperlipidemia overtakes fatty 
acid-induced potentiation of GLP-1 secretion. 
 
 
5.1 LIMITATIONS OF THE STUDIES 
Study I-III: In vitro studies obviously have inherent drawbacks, as the cells 
are isolated preventing paracrine and hormonal interactions, often exposed to 
an environment of overabundant nutrients etc. An additional drawback in 
culturing and studying models of the L-cells in vitro may be non-uniform 
distribution of receptors and transporters rendering an apical/basolateral 
surface well adjusted to the existing microenvironment in native L-cells, and 
the unfeasibility of apical/basolateral exposure to agents in vitro. Further, to 
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investigate lipotoxicity we tested only the saturated fatty acid palmitate. 
However, many different fatty acids are present in plasma and may have 
different effects. Also, various fatty acids may interact with each other to 
coordinate different pathological responses. 
Study I: To investigate the role of AMPK in the lipoprotective effect of 
metformin we used compound C, which is a relatively unspecific inhibitor of 
AMPK. Another limitation of this study may be that supratherapeutic 
concentrations of metformin were used to induce the lipoprotective effects. 
However, metformin has been shown to accumulate in tissues at higher 
concentrations than in blood [197]. Additionally, as the L-cells directly face 
the intestinal lumen, they may locally be exposed to very high metformin 
concentrations. 
Study II:  The role of ROS in p38 phosphorylation was not studied.  
Study III: Supratherapeutic concentrations of exendin-4 and insulin were 
used. Possible effects independent of GLP-1R signaling exerted by exendin 
(9-39) were not controlled for. Insulin effects on palmitate-induced ROS 
production was not monitored. 
Study IV: An obvious drawback of this study is the side-effects of oral gavage 
feeding as well as metformin treatment, where nausea and diarrhea were 
induced. In addition, the study encompassed relatively few animals. Further, 
metformin treatment could be optimized, perhaps by slowly increasing the 
dosage to achieve the final dose (as done in clinical practice to improve 
tolerability) and perhaps the duration of treatment could have been increased.  
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6 CONCLUSIONS 
 
• Palmitate induces lipotoxicity of GLP-1-secreting GLUTag cells 
through an increased ROS production and mediated by an increased 
phosphorylation of the kinases p38 and JNK. 
 
• Metformin induces lipoprotection of GLUTag cells through 
mechanisms independent of ROS production, but likely involving 
AMPK activation and p38 signaling. 
 
• The GLP-1R is expressed on GLUTag cells and acute as well as 
prolonged exposure to exendin-4 stimulates GLP-1 secretion through 
GLP-1R-dependent mechanisms. 
 
• Acute and prolonged exposure to insulin stimulates GLP-1 secretion 
from GLUTag cells. 
 
• Exendin-4 confers lipoprotection of GLUTag cells, while also 
reducing ROS production in response to simulated hyperlipidemia. 
Further, the lipoprotective effect of exendin-4 is mediated through the 
GLP-1R but independent of PKA. 
 
• Insulin also affords protection of GLUTag cells against lipotoxicity. 
 
• A high fat diet rapidly induces insulin resistance and a diabetic 
phenotype, while reducing the number of enteroendocrine L-cells and 
up-regulating the intestinal expression of GLP-1R mRNA. However, 
this reduction of L-cells and effects on the incretin system are likely to 
come secondary to development of diet-induced insulin resistance and 
T2D. 
 
• These findings may be of pathogenic significance in understanding 
mechanisms of the impaired incretin response characterizing T2D 
patients. 
 
• The results may also be harnessed to therapeutic advantage in efforts 
to enhance endogenous GLP-1 production, an approach that has 
hitherto received little attention but that may be superior to 
contemporary incretin-based antidiabetic therapy which does not 
faithfully mimick physiologic GLP-1 release in for instance terms of 
secretory pattern (e.g. pulsatility) and actions on topographically 
adjacent hormone receptors (e.g. in the portal vein). 
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Figure 4. Simplified scheme of conclusions. See text for details. ROS; Reactive Oxygen 
Species, p38; p38 mitogen-activated protein kinase, JNK; c-Jun N-terminal kinase, AMPK; 
5' adenosine monophosphate-activated protein kinase, PKA; protein kinase A, cAMP; 
cyclic adenosine monophosphate, GLP-1R; GLP-1 receptor, IR; Insulin receptor. 
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